About Metalloprotease TIKI2
Metalloprotease TIKI2 (TRABD2B) is a protein
from Homo sapiens identified by UniProt accession
A6NFA1, 517 residues long.
MolForge cross-references it against 0 known binders and
27 disease associations.
Target properties
| Protein name | Metalloprotease TIKI2 |
| UniProt accession | A6NFA1 |
| Gene | TRABD2B |
| Organism | Homo sapiens |
| Length | 517 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (27)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.42
- balding measurement · score 0.36
- urate measurement · score 0.29
- PHF-tau measurement · score 0.29
- peak expiratory flow · score 0.24
- hemoglobin measurement · score 0.18
- systolic blood pressure · score 0.11
- diastolic blood pressure · score 0.11
- renal cell carcinoma · score 0.07
- Abnormality of refraction · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-A6NFA1-F1 | alphafold | PREDICTED | 68.84 | — |
Amino-acid sequence (517 residues)
MHAALAGPLL AALLATARAR PQPPDGGQCR PPGSQRDLNS FLWTIRRDPP AYLFGTIHVP YTRVWDFIPD NSKAAFQAST RVYFELDLTD PYTISALASC QLLPHGENLQ DVLPHELYWR LKRHLDYVKL MMPSWMTPAQ RGKGLYADYL FNAIAGNWER KRPVWVMLMV NSLTERDVRF RGVPVLDLYL AQQAEKMKKT TGAVEQVEEQ CHPLNNGLNF SQVLFALNQT LLQQESVRAG SLQASYTTED LIKHYNCGDL SAVIFNHDTS QLPNFINTTL PPHEQVTAQE IDSYFRQELI YKRNERMGKR VMALLRENED KICFFAFGAG HFLGNNTVID ILRQAGLEVD HTPAGQAIHS PAPQSPAPSP EGTSTSPAPV TPAAAVPEAP SVTPTAPPED EDPALSPHLL LPDSLSQLEE FGRQRKWHKR QSTHQRPRQF NDLWVRIEDS TTASPPPLPL QPTHSSGTAK PPFQLSDQLQ QQDPPGPASS SAPTLGLLPA IATTIAVCFL LHSLGPS
Explore Metalloprotease TIKI2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets